Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763

Article  PubMed  Google Scholar 

Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P, Deshmukh RR (2020) Immunotherapies and combination strategies for immuno-oncology. Int J Mol Sci 21:5009. https://doi.org/10.3390/ijms21145009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X (2022) Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol 15:28. https://doi.org/10.1186/s13045-022-01247-x

Article  PubMed  PubMed Central  Google Scholar 

Lim M, Xia Y, Bettegowda C, Weller M (2018) Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 15:422–442. https://doi.org/10.1038/s41571-018-0003-5

Article  CAS  PubMed  Google Scholar 

Medikonda R, Dunn G, Rahman M, Fecci P, Lim M (2021) A review of glioblastoma immunotherapy. J Neurooncol 151:41–53. https://doi.org/10.1007/s11060-020-03448-1

Article  PubMed  Google Scholar 

Foreman PM, Friedman GK, Cassady KA, Markert JM (2017) Oncolytic Virotherapy for the treatment of malignant glioma. Neurotherapeutics 14:333–344. https://doi.org/10.1007/s13311-017-0516-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr (2020) A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27:S87-s97. https://doi.org/10.3747/co.27.5223

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:807–821. https://doi.org/10.1038/s41423-020-0488-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dobosz P, Dzieciątkowski T (2019) The intriguing history of cancer immunotherapy. Front Immunol 10:2965. https://doi.org/10.3389/fimmu.2019.02965

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abd-Aziz N, Poh CL (2022) Development of peptide-based vaccines for cancer. J Oncol 2022:9749363. https://doi.org/10.1155/2022/9749363

Article  CAS  PubMed  PubMed Central  Google Scholar 

Disis MLN, Guthrie KA, Liu Y, Coveler AL, Higgins DM, Childs JS, Dang Y, Salazar LG (2023) Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 nonrandomized clinical trial. JAMA Oncol 9:71–78. https://doi.org/10.1001/jamaoncol.2022.5143

Article  PubMed  Google Scholar 

Paston SJ, Brentville VA, Symonds P, Durrant LG (2021) Cancer vaccines, adjuvants, and delivery systems. Front Immunol 12:627932. https://doi.org/10.3389/fimmu.2021.627932

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Muller F, Rhee I, Yadav M, Dobrin A, Sadelain M, Luksza M, Cohen N, Tang L, Basturk O, Gonen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D’Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Tureci O, Greenbaum BD, Jarnagin WR, Drebin J, O’Reilly EM, Balachandran VP (2023) Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618:144–150. https://doi.org/10.1038/s41586-023-06063-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bastin DJ, Montroy J, Kennedy MA, Martel AB, Shorr R, Ghiasi M, Boucher DM, Wong B, Gresham L, Diallo JS, Fergusson DA, Lalu MM, Kekre N, Auer RC (2023) Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials. Sci Rep 13:3347. https://doi.org/10.1038/s41598-023-29630-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Enokida T, Moreira A, Bhardwaj N (2021) Vaccines for immunoprevention of cancer. J Clin Invest 131:e146956. https://doi.org/10.1172/JCI146956

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW (2021) The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification. Clin Cancer Res 27:689–703. https://doi.org/10.1158/1078-0432.CCR-20-0245

Article  CAS  PubMed  Google Scholar 

Chang R, Gulley JL, Fong L (2023) Vaccinating against cancer: getting to prime time. J Immunother Cancer 11:e006628. https://doi.org/10.1136/jitc-2022-006628

Article  PubMed  PubMed Central  Google Scholar 

Blass E, Ott PA (2021) Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 18:215–229. https://doi.org/10.1038/s41571-020-00460-2

Article  PubMed  PubMed Central  Google Scholar 

Lang F, Schrors B, Lower M, Tureci O, Sahin U (2022) Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov 21:261–282. https://doi.org/10.1038/s41573-021-00387-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Weiss T, Neidert MC, Toussaint NC, Naghavian R, Selles Moreno C, Foege M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrors B, Shin JH, McKay R, Wu CJ, Lutterotti A, Sospedra M, Moch H, Greiner EF, Bodenmiller B, Regli L, Weller M, Roth P, Martin R (2022) Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4 + T-cell responses in glioblastoma. Clin Cancer Res 28:5368–5382. https://doi.org/10.1158/1078-0432.CCR-22-1741

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rothlin CV, Hille TD, Ghosh S (2021) Determining the effector response to cell death. Nat Rev Immunol 21:292–304. https://doi.org/10.1038/s41577-020-00456-0

Article  CAS  PubMed  Google Scholar 

Boada-Romero E, Martinez J, Heckmann BL, Green DR (2020) The clearance of dead cells by efferocytosis. Nat Rev Mol Cell Biol 21:398–414. https://doi.org/10.1038/s41580-020-0232-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bastin DJ, Quizi J, Kennedy MA, Kekre N, Auer RC (2022) Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies. Cytotherapy 24:979–989. https://doi.org/10.1016/j.jcyt.2022.03.010

Article  CAS  PubMed  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330

Article  CAS  PubMed  Google Scholar 

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W, European Association for Neuro-Oncology Task Force on G (2017) European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315–e329. https://doi.org/10.1016/S1470-2045(17)30194-8

Article  PubMed  Google Scholar 

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316. https://doi.org/10.1001/jama.2017.18718

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kornblith PK, Welch WC, Bradley MK (1993) The future of therapy for glioblastoma. Surg Neurol 39:538–543. https://doi.org/10.1016/0090-3019(93)90041-x

Article  CAS  PubMed  Google Scholar 

Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O’Rourke DM, D’Ambrosio A, Bruce JN, Parsa AT (2017) Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy. Clin Cancer Res 23:3575–3584. https://doi.org/10.1158/1078-0432.Ccr-16-1369

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao B, Wu J, Li H, Wang Y, Wang Y, Xing H, Wang Y, Ma W (2023) Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. Cell Commun Signal 21:74. https://doi.org/10.1186/s12964-023-01098-0

Article  PubMed  PubMed Central  Google Scholar 

Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert JM, LaRocca R, O’Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS (2019) A randomized double-blind placeb